Eli Lilly and Company (LLY)
| Market Cap | 901.86B +12.8% |
| Revenue (ttm) | 65.18B +44.7% |
| Net Income | 20.64B +94.9% |
| EPS | 22.95 +96.0% |
| Shares Out | 893.36M |
| PE Ratio | 43.99 |
| Forward PE | 29.37 |
| Dividend | $6.92 (0.69%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 3,266,509 |
| Open | 1,023.86 |
| Previous Close | 1,023.22 |
| Day's Range | 1,002.46 - 1,028.65 |
| 52-Week Range | 623.78 - 1,133.95 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 1,165.58 (+15.46%) |
| Earnings Date | Feb 4, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,165.58, which is an increase of 15.46% from the latest price.
News
Our Top 10 High Growth Dividend Stocks - February 2026
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally l...
CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co , granting it certain rights to develop and commercialise clazakizumab, an antibody aimed a...
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company.
Lilly targets India as global export hub amid booming Mounjaro sales, executive says
Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as part of its previously committed $1 billion investment to contrac...
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exception...
Lilly to participate in TD Cowen's 46th Annual Health Care Conference
INDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice presiden...
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on pr...
Is LLY Stock Headed To $1,350?
Following record-breaking adoption of its GLP-1 portfolio and positive Phase 3 data in Alzheimer's treatments, LLY has entered a new growth tier. Our multi-factor analysis suggests now is an opportune...
Prices, pipelines and patent cliffs: Inside pharma's big reset
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision by the U.S. Food and Drug Administration ...
Baron Opportunity Fund Q4 2025 Contributors And Detractors
SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. Eli Lilly shares contributed to performance as Zepbound continues to gain share for the treatment of ...
What Will Drive Eli Lilly Stock's Next Breakout?
Eli Lilly stock (NYSE: LLY) has been on a tear, surging over 60% in just the last six months. This momentum is part of a broader pattern of explosive growth; the stock has repeatedly rallied more than...
Lilly's bowel disease drug gets approval in China
Eli Lilly has won Chinese regulators' approval for its drug to treat chronic inflammatory bowel disease, expanding the treatment's use to the world's second-largest pharmaceutical market, it said on W...
Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments
The strategic move is seen as a significant step in enhancing Lilly's capabilities in genetic medicine, adding pressure as broader markets edged lower.
Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion
Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.
Eli Lilly Stock Rises. It's Acquiring This Cell Therapy Company for $2.4 Billion.
Lilly agrees to acquire Orna Therapeutics in an all-cash deal.
Lilly to buy Orna Therapeutics for up to $2.4 billion
Eli Lilly will acquire therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said on Monday.
Lilly to acquire Orna Therapeutics to advance cell therapies
Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term inn...
Innovent Biologics Strikes Partnership Deal With Eli Lilly
Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.
China's Innovent clinches new Lilly deal for immunology, cancer drug development
China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S. drugmaker will pay $350 million upfront and as much as $8.5 billion more ...
LLY Gains on NVO Losses & Outlook for Weight Loss Drug Trade
Novo Nordisk (NVO) is down 40% year-over-year while Eli Lilly (LLY) is up 30%. It's a shake-up in the GLP-1 trade that few expected, especially with Matt Maley pointing out that Novo Nordisk originall...
Weight-loss drugs to compete on biggest stage with Super Bowl ads
Companies looking to sell weight-loss drugs directly to consumers, including Novo Nordisk's Wegovy, will shell out millions of dollars for celebrity-filled ads during Sunday's Super Bowl with its prom...
Eli Lilly: Positives Outweigh The Concerns
Eli Lilly and Company's price jump following its latest earnings release is completely justified going by both the performance and guidance. Both LLY revenue and EPS growth exceeded guidance, despite ...